U.S. Markets open in 5 hrs 21 mins

TARIS Announces Presentation of Clinical Data for TAR-302 for Overactive Bladder

Data to be presented at upcoming International Continence Society Annual Meetingin Gothenburg, Sweden in September

LEXINGTON, Mass., July 25, 2019 /PRNewswire/ -- TARIS Bio™, a biopharmaceutical company developing transformational therapies to treat people with debilitating urological disorders, announced today that results of the company's Phase 1b study of TAR-302 for the treatment of overactive bladder (OAB) will be presented in a podium session on Wednesday, September 4th at the Annual Meeting of the International Continence Society (ICS) in Gothenburg, Sweden. The presentation will detail the safety, tolerability, pharmacokinetics and preliminary efficacy data including a durable benefit of TAR-302, which was administered to 11 OAB patients for six weeks. The abstract is available on the ICS website.

TARIS Biomedical (PRNewsfoto/TARIS)

TAR-302 is TARIS' lead investigational program in overactive bladder. The system is designed to continuously release the antimuscarinic agent trospium in the bladder for multiple months, at local concentrations several times higher than is achievable with oral treatment with negligible systemic exposure. TARIS believes that TAR-302 has the potential to improve efficacy, reduce side-effects, and unlock powerful new pharmacology compared with oral therapy. TARIS is evaluating TAR-302 to address unmet needs in both idiopathic and neurogenic OAB; a Phase 1 study in overactive bladder patients investigating the use of TAR-302 for 12 continuous weeks is ongoing.

"TARIS believes TAR-302 may become a new standard of care for OAB patients not well managed with current oral therapies," said Christopher Cutie, M.D., Chief Medical Officer at TARIS. "We are excited to share these data at ICS, which offer initial demonstration of this potential benefit."

Details of the presentation:
Abstract Number: 185
Title: Continuous Intravesical Delivery of Trospium Chloride Significantly Improves OAB Symptoms: Results of a Phase 1b Study
Presenter: Christopher Cutie, M.D., Chief Medical Officer at TARIS
Session & Location: Overactive Bladder - Scientific Podium Short Oral Session 8 (Hall K, Swedish Exhibition & Congress Centre, Gothenburg)
Date and Time: Wednesday, September 4, 2019, 15:15 - 15:22 CEST

About Overactive Bladder
One out of every six American adults suffers from symptoms of overactive bladder (OAB). OAB is characterized by urinary urgency, frequency and incontinence; these symptoms have a profound negative impact on patients' daily activities and quality of life. OAB can result from an underlying neurologic injury (neurogenic detrusor overactivity, or NDO) or from unclear etiology (idiopathic overactive bladder, or iOAB). Antimuscarinic agents are available in oral and transdermal dosage forms, but their utility is limited by systemic side effects.

About TARIS Bio™
TARIS Bio is developing transformational therapies to treat people with debilitating urological disorders. The company is unlocking novel epithelial biology through continuous disease engagement with its unique platform. TARIS® has lead programs in bladder cancer and overactive bladder, which position the company to improve patient health and redefine urologic care. www.tarisbio.com

 

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/taris-announces-presentation-of-clinical-data-for-tar-302-for-overactive-bladder-300890703.html